Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  ProQR Therapeutics  /  ProQR Therapeutics 2019

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel ProQR Therapeutics NV OTC:PRQR.Q, NL0010872495

  • 2,010 24 apr 2024 22:00
  • -0,010 (-0,50%) Dagrange 1,970 - 2,040
  • 36.411 Gem. (3M) 204,8K

ProQR Therapeutics 2019

2.656 Posts
Pagina: «« 1 ... 53 54 55 56 57 ... 133 »» | Laatste | Omlaag ↓
  2. forum rang 7 4finance 23 juni 2019 09:57
    quote:

    Wolfgang schreef op 22 juni 2019 22:07:

    Ik heb proqr al van 3.50$ maar ben er nu ook uit, toch voorlopig. Na het uitstellen van de Usher resultaten is het vertrouwen toch wat zoek. zijn er dit jaar nog catalysts? Als ik op de website kijk gaat de rest van het jaar rustig worden. Ik denk wat meer affimed te kopen.
    Zo kijk er ook tegen aan. Affimed kon nog wel eens een behoorlijke rit gaan maken.
  3. Ontop1 23 juni 2019 19:11
    quote:

    Tom3 schreef op 21 juni 2019 22:35:

    Ik ben aan het daytraden met Affimed geweest, heb ProQR zijdelings gevolgd. Stond bij het scheiden van de markt nog even in de plus. Ik neig er nu naar te geloven dat De Boer zijn woorden over Usher, de kurk van ProQR`s toekomstig bestaan, onzorgvuldig waren gekozen.
    Ben ook aan het daytraden met Affimed en Bellicum en dat gaat me wonderwel goed af
    Ingestapt Proqr was nog teveel op 10.08
  4. [verwijderd] 24 juni 2019 09:51
    i read the comments of some here .. and its obvious to me that people dont understand the potential of Proqr , its differentiation from other biotech companies and the beauty in this company. all of its achievements are due in great part because of the vision and strategic setup of its CEO. I see people talk about Affimed here a company which in 20 years and more of existence barely has a viable product. Proqr has built a platform in record time which could bring 2 drugs to market in 2023 and many more close to market. In addition it has a platform to be able to drug thousands of orphan diseases and people on this board instead of talking about the company, the technology , are talking about failed companies.. even those have at time price surges. but is this a board for Proqr or for day trading biotech stocks? anyway.
  5. [verwijderd] 24 juni 2019 09:56
    as to Usher not coming up with intermediate results.. Usher is a form of LA, the drug that Proqr has shown it works and makes blind people see again after 15 years of blindness . what Proqr now needs is speed to market. not stopping the trial for showing intermediate results which where of only 3 people may had been a strategic decision for I can speculate 2 things
    1) faster time to market
    2) not showing the competition whether the drug works / doesnt work.. which would make others copy Proqr target.

    Proqr is secretive and its very good that it is like that.. because ultimately we dont want 16 dollars for our stock, or 25 .. we want 100 , possibly higher much higher in the coming years.
  6. Guy2024 24 juni 2019 12:02
    quote:

    joel12 schreef op 24 juni 2019 09:56:

    as to Usher not coming up with intermediate results.. Usher is a form of LA, the drug that Proqr has shown it works and makes blind people see again after 15 years of blindness . what Proqr now needs is speed to market. not stopping the trial for showing intermediate results which where of only 3 people may had been a strategic decision for I can speculate 2 things
    1) faster time to market
    2) not showing the competition whether the drug works / doesnt work.. which would make others copy Proqr target.

    Proqr is secretive and its very good that it is like that.. because ultimately we dont want 16 dollars for our stock, or 25 .. we want 100 , possibly higher much higher in the coming years.
    Je bent wel heel erg enthousiast over Proqr Joel.Je zou mss kunnen gelijk hebben,maar dat zal de toekomst moeten uitwijzen.Dat De Boer er nu maar eens werk van maakt want het aandeel staat ondertussen bijna 60% lager.In Affimed geloof je dus niet,Tom zal het niet graag horen.
  8. forum rang 6 Tom3 24 juni 2019 12:26
    quote:

    joel12 schreef op 24 juni 2019 09:51:

    i read the comments of some here .. and its obvious to me that people dont understand the potential of Proqr , its differentiation from other biotech companies and the beauty in this company. all of its achievements are due in great part because of the vision and strategic setup of its CEO. I see people talk about Affimed here a company which in 20 years and more of existence barely has a viable product. Proqr has built a platform in record time which could bring 2 drugs to market in 2023 and many more close to market. In addition it has a platform to be able to drug thousands of orphan diseases and people on this board instead of talking about the company, the technology , are talking about failed companies.. even those have at time price surges. but is this a board for Proqr or for day trading biotech stocks? anyway.
    Hi Joel, when did you buy this stock? If you have entered somewhere when it was $ 20 or when it was $ 3 makes a huge difference. Existing shareholders will blame De Boer for his 2 mistakes this year and the drop in the share price. Mr Market has low expectations as it is not clear why de Boer has chosen to delay the interim results. A delay ads to the perception of a failure, otherwise the share price would now have been $ 20 again.
  9. [verwijderd] 24 juni 2019 12:32
    the share price at any given moment is not indicative of future potential. i was wrong to had not sold tactically more at 25, PROQR at the time was overvalued based on its development. so the fact that the share is 50 percent off its intermediate high its acceptable and of course the price could quickly go up as the company is pending major business developments, dont forget has 2 very interesting drugs to partner the CF and the Huntington .. as well as the RNA editing.
    in addition it does have in fall a major readout the phase 1/2 for Leber.

    As to affimed it has a following .. it became a followers stock doesnt matter what anyone would say the followers will believe in it .. and it does have a merit but the company doesnt have the potential anywhere near PROQR. as to the CEO Adi.. he did millions of mistakes I wonder how come he is still there .. btw the major holder of Affimed sold if not close to all its stake in the company so what I think about the company and its CEO is conquered by the company that at one point owned 20perc or more . but am not here to discuss affimed , its a Proqr board no?
  10. forum rang 6 Tom3 24 juni 2019 14:10
    Lets stick to ProQR, I would love to see a partnership in order to prevent further dilution. CF is 2 years "on the market" but nobody showed real interest. Why? I know Dutch Life Sciences Partners once had a significant stake in ProQR, they sold everything. Compared to the Tschira Bros I assume they have the brains and patience.
  11. RP91 24 juni 2019 14:24
    quote:

    nelis h schreef op 24 juni 2019 12:19:

    Affimed een mooi PB vandaag, misschien moet Joel dat even lezen om te zien wat voor effekt AFM13 op Keytruda heeft. Dat moet Merck toch wel opgevallen zijn
    Wat staat er in het pb? Ik heb het namelijk nog niet gelezen, maar in voorbeurs staat affimed al meer dan 5% in de min.
  12. forum rang 5 RW1963 24 juni 2019 15:50
    quote:

    RP91 schreef op 24 juni 2019 14:24:

    [...]
    Wat staat er in het pb? Ik heb het namelijk nog niet gelezen, maar in voorbeurs staat affimed al meer dan 5% in de min.
    Helaas, Affimed is al weer dalende, evenals ProQR. Gelukkig houd Galapagos nog redelijk stand.

    Kunnen alle reacties hier s.v.p. in het Nederlands, dit is tenslotte een Nederlandse site.
  13. [verwijderd] 24 juni 2019 16:08
    proqr says it has cash until 2021. if it gets good results in fall or and next year it may dillute but higher valuation
    as to its CF drug I have few possible explanations.
    1) they are still trying to figure out the mode of action. once that its clear there will be plenty to partner. but it has been a sticking issue dont know if they have solved it.
    2) the RNA editing could solve probably several CF mutations.. maybe all? so proqr has maybe a problem with partnering a product for a disease for which they are having another drug up and coming for
    3) and last.. the initial drug was also some type of RNA editing, maybe they dont want to give it out to not let others decipher how rna editing works.

    or none of the above and they are still trying to get the best partner , which its time is coming ...
  16. forum rang 6 Tom3 24 juni 2019 16:55
    quote:

    Guy-vdk schreef op 24 juni 2019 16:35:

    Affimed een mooi PB? Ik zie ze toch 10% lager staan,zo goed zal dat dan toch niet geweest zijn..
    Affimed heeft in mijn ogen onvoldoende toegelicht waarom de progression free survival terug gelopen is van 70+% naar 45% (dat was volledig de verdienste van Keytruda). Ze zijn in hun pr net zo oenig als ProQR. Zakkenwassers.
2.656 Posts
Pagina: «« 1 ... 53 54 55 56 57 ... 133 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!